Recent Paradigm Shifts in the Diagnosis and Treatment of Rheumatoid Arthritis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Rheumatoid arthritis (RA) is a progressive inflammatory disease with severe symptoms of pain and stiffness. Chronic persistent inflammation of RA often leads to joint destruction, deformity and limitation of function, which ultimately results in significant deterioration of quality of life (QoL). RA is characterized pathogenetically by immunologically driven, chronic synovitis, and production of autoantibodies, such as rheumatoid factor and anti-cyclic citrullinated peptide antibodies. Although the cause of RA is yet unknown, advances in the molecular biology led to in-depth understanding of its pathogenesis, and have fostered the recent development of novel treatments. The last decade has seen the dramatic change in the landscape of RA treatment with more aggressive therapy early in the disease course and with treatment guided by a structured assessment of disease activity, with the ultimate goal of reaching remission. In addition, prevention and control of joint damage and improvement in QoL are important goals. To achieve these goals, a multidisciplinary approach to reduce disease activity with disease modifying antirheumatic drugs and biological therapy is needed. We also need to find ways to identify those patients who are at risk for more rapid disease progression who would benefit from intensive therapy early in the course of disease.
Abstract
Rheumatoid arthritis (RA) is a progressive inflammatory disease with severe symptoms of pain and stiffness. Chronic persistent inflammation of RA often leads to joint destruction, deformity and limitation of function, which ultimately results in significant deterioration of quality of life (QoL). RA is characterized pathogenetically by immunologically driven, chronic synovitis, and production of autoantibodies, such as rheumatoid factor and anti-cyclic citrullinated peptide antibodies. Although the cause of RA is yet unknown, advances in the molecular biology led to in-depth understanding of its pathogenesis, and have fostered the recent development of novel treatments. The last decade has seen the dramatic change in the landscape of RA treatment with more aggressive therapy early in the disease course and with treatment guided by a structured assessment of disease activity, with the ultimate goal of reaching remission. In addition, prevention and control of joint damage and improvement in QoL are important goals. To achieve these goals, a multidisciplinary approach to reduce disease activity with disease modifying antirheumatic drugs and biological therapy is needed. We also need to find ways to identify those patients who are at risk for more rapid disease progression who would benefit from intensive therapy early in the course of disease.
참고문헌 (51)
- Steven S. Storage, "Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis", The Korean Journal of Internal Medicine, 25(1), pp.1~17 (2010), 대한내과학회
- 이광훈, "Inflammatory Polyarthritis in a Patient with Psoriasis: Is It Psoriatic Arthritis or Rheumatoid Arthrirtis?", The Korean Journal of Internal Medicine, 25(2), pp.224~226 (2010), 대한내과학회
- Szekanecz Z, "Chemokines and angiogenesis in rheumatoid arthritis", Front Biosci (Elite Ed), 1, pp.44~51 (2009)
- Polzer K, "Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints", Ann Rheum Dis, 67, pp.1610~1616 (2008)
- Chabaud M, "Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines", J Immunol, 161, pp.409~414 (1998)
- Miossec P, "Interleukin-17 and type 17 helper T cells", N Engl J Med, 361, pp.888~898 (2009)
- Chen Z, "Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation", Semin Immunol, 19, pp.400~408 (2007)
- Nadkarni S, "Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta", J Exp Med, 204, pp.33~39 (2007)
- Schwartz RH, "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7", BB1 in interleukin-2 production and immunotherapy, 1992, pp.71, 1065~1068
- Genovese MC, "Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy", Ann Rheum Dis, 67, pp.547~554 (2008)
- Edwards JC, "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis", N Engl J Med, 350, pp.2572~2581 (2004)
- Feldmann M, "Rheumatoid arthritis", Cell, 85, pp.307~310 (1996)
- Hirano T, "Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin", Nature, 324, pp.73~76 (1986)
- Nemeth E, "IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin", J Clin Invest, 113, pp.1271~1276 (2004)
- Nishimoto N, "Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab", Ann Rheum Dis, 66, pp.1162~1167 (2007)
- Chabaud M, "IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis", Arthritis Res, 3, pp.168~177 (2001)
- Kirkham BW, "Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort)", Arthritis Rheum, 54, pp.1122~1131 (2006)
- Hueber W, "Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis", Sci Transl Med, 2, pp.52ra72~ (2010)
- Bradfield PF, "Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue", Arthritis Rheum, 48, pp.2472~2482 (2003)
- Filer A, "Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils", Arthritis Rheum, 54, pp.2096~2108 (2006)
- Visser H, "How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis", Arthritis Rheum, 46, pp.357~365 (2002)
- Gravallese EM, "Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis", Am J Pathol, 152, pp.943~951 (1998)
- McInnes IB, "The pathogenesis of rheumatoid arthritis", N Engl J Med, 365, pp.2205~2219 (2011)
- Simsek I, "TNF inhibitors: new and old agents for rheumatoid arthritis", Bull NYU Hosp Jt Dis, 68, pp.204~210 (2010)
- Ohta S, "Optimal dose prediction by pharmacokinetic and biomarker response of subcutaneous tocilizumab treatment: a phase I", II study evaluating the safety, pharmacokinetics and clinical response in patients with rheumatoid arthritis, 2010, pp.62(Suppl 10), S1115~
- Guyot P, "Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis", Arthritis Res Ther, 13, pp.R204~ (2011)
- Buch MH, "New therapies in the management of rheumatoid arthritis", Curr Opin Rheumatol, 23, pp.245~251 (2011)
- Genovese MC, "Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: results of a phase IIb study", Arthritis Rheum, 62, pp.L9~ (2010)
- Kremer JM, "The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo", Arthritis Rheum, 60, pp.1895~1905 (2009)
- Tanaka Y, "Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate", Arthritis Care Res, 63, pp.1150~1158 (2011)
- Kremer J, "Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs", Ann Rheum Dis, 70(Suppl 3), pp.170~ (2011)
- Weinblatt ME, "An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis", N Engl J Med, 363, pp.1303~1312 (2010)
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- Aletaha D, "2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2010, pp.69, 1580~1588
- Aletaha D, "2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2010, pp.62, 2569~2581
- Aggarwal R, "Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis", Arthritis Rheum, 61, pp.1472~1483 (2009)
- Smolen JS, "Treating rheumatoid arthritis to target: recommendations of an international task force", Ann Rheum Dis, 69, pp.631~637 (2010)
- Salomon-Escoto KI, "Assessment of control of rheumatoid arthritis disease activity", Best Pract Res Clin Rheumatol, 25, pp.497~507 (2011)
- Horton SC, "Established rheumatoid arthritis: rationale for best practice: physicians’ perspective of how to realise tight control in clinical practice", Best Pract Res Clin Rheumatol, 25, pp.509~521 (2011)
- Smolen JS, "Monitoring rheumatoid arthritis", Curr Opin Rheumatol, 23, pp.252~258 (2011)
- Felson DT, "The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials", Arthritis Rheum, 36, pp.729~740 (1993)
- van der Heijde DM, "Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score", Ann Rheum Dis, 49, pp.916~920 (1990)
- Prevoo ML, "Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score", Br J Rheumatol, 35, pp.1101~1105 (1996)
- Prevoo ML, "Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis", Arthritis Rheum, 38, pp.44~48 (1995)
- van Tuyl LH, "Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome", Ann Rheum Dis, 71, pp.33~37 (2012)
- Aletaha D, "The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis", Clin Exp Rheumatol, 23(5 Suppl 39), pp.S100~S108 (2005)
- Breedveld FC, "Understanding emerging treatment paradigms in rheumatoid arthritis", Arthritis Res Ther, 13(Suppl 1), pp.S3~ (2011)
- "American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update", Arthritis Rheum, 46, pp.328~346 (2002)
- Chen S, "Pain and rheumatoid arthritis: an update", Drug Topics, 3, pp.47~56 (2000)
- Solau-Gervais E, "Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody", Rheumatology, 45, pp.1121~1124 (2006)
- Kim HA, "The rate of attaining low disease activity with Methotrexate (MTX) based non-biological DMARD in patients with rheumatoid arthritis (RA): T-2-T data from 4 university affiliated Korean rheumatology clinics", J Rheum Dis, 19, pp.S142~ (2012)